BACTERIAL-BINDING PROTEIN FOR IGE

IGE 的细菌结合蛋白

• 批准号: 6226943
• 负责人: MICHAEL D. BOYLE
• 金额: $ 8.21万
• 依托单位: LABORATORY RESOURCES, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6226943
• 关键词: allergens; bacterial proteins; binding proteins; chromatography; diagnosis design /evaluation; enzyme linked immunosorbent assay; immunoglobulin E; immunologic assay /test; protein purification; reagent /indicator; western blottings

Allergic rhinitis affects 20% of the population in the USA and has a serious financial impact in both lost time and medical costs for physician visits and medication. Currently, treatment falls into three categories. The first is to identify the allergen and develop a strategy of avoidance by the patient. The second strategy is the use of pharmacological agents to prevent symptoms and the third approach is desensitization to a specific allergen. The most cost-effective strategy is that of allergen avoidance and hence, there is substantial benefit for reliable assays that can detect the allergen to which a patient is sensitive. Because skin testing is unpleasant for the patient and requires significant physician involvement, radioallergosorbent tests (RAST) are the optimal strategy to identify allergic reactivities in atopic individuals. The focus of this proposal is to improve the sensitivity of automated in vitro testing for allergens by replacing an expensive detection reagent, a specific antibody to human epsilon heavy chains, with a low-cost high affinity bacterial IgE binding protein. The reagent will improve sensitivity and reduce false negative results for a key screening test to identify the causative agent of allergic responses in atopic individuals. PROPOSED COMMERCIAL APPLICATION: The commercial application of the technology is to replace an anti-IgE antibody with a higher affinity specific bacterial protein. This product will find applications in diagnostic allergy testing and may provide new strategies for developing a novel therapeutic to prevent allergic reactions in atopic patients.

过敏性鼻炎影响美国20%的人口，并且在医生就诊和药物治疗的时间损失和医疗费用方面具有严重的经济影响。目前，治疗福尔斯分为三类。首先是确定过敏原，并制定患者的避免策略。第二种策略是使用药物来预防症状，第三种方法是对特定过敏原脱敏。最具成本效益的策略是避免过敏原，因此，可靠的检测方法可以检测患者敏感的过敏原，这是非常有益的。由于皮肤试验对患者来说是不愉快的，需要大量的医生参与，放射性过敏原吸附试验（RAST）是识别特应性个体过敏反应的最佳策略。该提案的重点是通过用低成本的高亲和力细菌IgE结合蛋白代替昂贵的检测试剂（针对人IgE重链的特异性抗体）来提高自动化体外过敏原检测的灵敏度。该试剂将提高敏感性，并减少假阴性结果的关键筛选试验，以确定过敏性个体过敏反应的病原体。拟定商业应用：该技术的商业应用是用更高亲和力的特异性细菌蛋白代替抗IgE抗体。该产品将在诊断过敏测试中找到应用，并可能为开发新的治疗方法提供新的策略，以防止特应性患者的过敏反应。